A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice

Molecular Neurodegeneration

Laura H. Jacobson⁵  Matthias Staufenbiel²  Derya R. Shimshek⁸  Wilfried Frieauff¹  Peter Schmid⁶  Barbara Vogg⁷  Karen Beltz³  Grit Laue³  Marina Tintelnot-Blomley⁴  Rainer M. Lueoend⁴  Siem Jacob Veenstra⁴  Rainer Machauer⁴  Heinrich Rueeger⁴  Ulf Neumann⁸ 

[1] Preclinical Safety, NIBR, Basel, Switzerland;Hertie Institute for Clinical Brain Research, Tübingen, Germany;Metabolism and Pharmacokinetics, NIBR, Basel, Switzerland;Global Discover Chemistry, NIBR, Basel, Switzerland;The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Parkville, Australia;Swiss Tropical and Public Health Institute, Basel, Switzerland;DMPK, NIBR, Basel, Switzerland;Neuroscience, Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland

关键词: Neuroinflammation;    Amyloid-β;    Inhibitor;    BACE-1;    Alzheimer’s disease;   

Others  :  1224813
DOI  :  10.1186/s13024-015-0033-8

 received in 2015-06-11, accepted in 2015-08-03,  发布年份 2015

【 摘 要 】

Background

Alzheimer’s disease (AD) is the most common form of dementia, the number of affected individuals is rising, with significant impacts for healthcare systems. Current symptomatic treatments delay, but do not halt, disease progression. Genetic evidence points to aggregation and deposition of amyloid-β (Aβ) in the brain being causal for the neurodegeneration and dementia typical of AD. Approaches to target Aβ via inhibition of γ-secretase or passive antibody therapy have not yet resulted in substantial clinical benefits. Inhibition of BACE1 (β-secretase) has proven a challenging concept, but recent BACE1inhibitors can enter the brain sufficiently well to lower Aβ. However, failures with the first clinical BACE1 inhibitors have highlighted the need to generate compounds with appropriate efficacy and safety profiles, since long treatment periods are expected to be necessary in humans.

Results

Treatment with NB-360, a potent and brain penetrable BACE-1 inhibitor can completely block the progression of Aβ deposition in the brains of APP transgenic mice, a model for amyloid pathology. We furthermore show that almost complete reduction of Aβ was achieved also in rats and in dogs, suggesting that these findings are translational across species and can be extrapolated to humans. Amyloid pathology may be an initial step in a complex pathological cascade; therefore we investigated the effect of BACE-1 inhibition on neuroinflammation, a prominent downstream feature of the disease. NB-360 stopped accumulation of activated inflammatory cells in the brains of APP transgenic mice. Upon chronic treatment of APP transgenic mice, patches of grey hairs appeared.

Conclusions

In a rapidly developing field, the data on NB-360 broaden the chemical space and expand knowledge on the properties that are needed to make a BACE-1 inhibitor potent and safe enough for long-term use in patients. Due to its excellent brain penetration, reasonable oral doses of NB-360 were sufficient to completely block amyloid-β deposition in an APP transgenic mouse model. Data across species suggest similar treatment effects can possibly be achieved in humans. The reduced neuroinflammation upon amyloid reduction by NB-360 treatment supports the notion that targeting amyloid-β pathology can have beneficial downstream effects on the progression of Alzheimer’s disease.

【 授权许可】

   
2015 Neumann et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

【 参考文献 】

• [1]Masters CL, Selkoe DJ. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med. 2012; 2:a006262.
• [2]Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M et al.. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014; 370:322-33.
• [3]Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S et al.. Alzheimer’s disease cooperative study steering committee; Solanezumab study group phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014; 370:311-21.
• [4]Wang J, Tan L, Wang HF, Tan CC, Meng XF, Wang C et al.. Anti-inflammatory drugs and risk of Alzheimer’s disease: an updated systematic review and meta-analysis. J Alz Dis. 2015; 44:385-96.
• [5]Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O et al.. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013; 12:357-67.
• [6]Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC et al.. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem. 2014; 130:4-28.
• [7]Yan R, Vassar R. Targeting the β secretase BACE1 for Alzheimer’s disease therapy. Lancet Neurol. 2014; 13:319-29.
• [8]Oehlrich D, Prokopcova H, Gijsen HJM. The evolution of amidine-based brain penetrant BACE1 inhibitors. Bioorg Med Chem Lett. 2014; 24:2033-45.
• [9]Swahn B-M, Kolmodin K, Karlström S, von Berg S, Söderman P, Holenz J et al.. Design and Synthesis of β-Site Amyloid predursor Protein Cleaving enzyme (BACE1) inhibitors with in vivo Brain reduction of β-Amyloid Peptides. J Med Chem. 2012; 55:9346-61.
• [10]May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ et al.. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans. J Neurosci. 2015; 35:1199-210.
• [11]May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN et al.. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci. 2011; 31:16507-16.
• [12]Fielden MR, Werner J, Jamison JA, Coppi A, Hickman D, Dunn RT, et al. Retinal toxicity induced by a novel β-secretase inhibitor in the sprague-dawley rat. Toxicol Pathol. 2015;43:581–92.
• [13]Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeability assay in the description of passive absorption processes. J Med Chem. 1998; 41:1007-10.
• [14]Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD et al.. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008; 36:268-75.
• [15]Head E. A canine model of human aging and Alzheimer’s disease. Biochim Biophys Acta. 2013; 1832:1384-9.
• [16]Lu Y, Barton HA, Leung L, Zhang L, Hajos-Korcsok E, Nolan CE et al.. Cerebrospinal fluid β-Amyloid turnover in the mouse, dog, monkey and human evaluated by systematic quantitative analyses. Neurodeg Dis. 2013; 12:36-50.
• [17]Rabe S, Reichwald J, Ammaturo D, de Strooper B, Saftig P, Neumann U et al.. The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing. J Neurochem. 2011; 119:231-9.
• [18]McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB et al.. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem. 2007; 282:26326-34.
• [19]Yamakawa H, Yagishita S, Futai E, Ishiura S. β-Secretase inhibitor potency is decreased by aberrant β-cleavage location of the “Swedish Mutant” amyloid precursor protein. J Biol Chem. 2010; 285:1634-42.
• [20]Thakker DR, Sankaranarayanan S, Weatherspoon MR, Harrison J, Pierdomenico M, Heisel JM et al.. Centrally delivered BACE1 inhibitor activates microglia, and reverses amyloid pathology and cognitive deficit in aged Tg2576 mice. J Neurosc. 2015; 35:6931-6.
• [21]Abramowski D, Wiederhold KH, Furrer U, Jaton AL, Neuenschwander A, Runser MJ et al.. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther. 2008; 327:411-24.
• [22]Jacobsen H, Ozmen L, Caruso A, Narquizian R, Hilpert H, Jacobsen B et al.. Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice. J Neurosci. 2014; 34:11621-30.
• [23]Obulesu M, Jhansilakshimi M. Neuroinflammation in Alzheimer’s disease: an understanding of physiology and pathology. Int J Neurosci. 2014; 124:227-35.
• [24]Heneka MT, Rodrigues JJ, Verkhratsky A. Neuroglia in neurodegeneration. Brain Res Rev. 2010; 63:189-211.
• [25]Latta CH, Brothers HM, Wilcock DM. Neuroinflammation in Alzheimer’s disease; a source of heterogeneity and target for personalized therapy. Neuroscience, ahead of print. doi:10.1016/j.neuroscience.2014.09.061.
• [26]Rochin L, Hurbain I, Serneels L, Fort C, Watt B, Leblanc P et al.. BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells. Proc Natl Acad Sci USA. 2013; 110:10658-63.
• [27]Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012; 2:a006346.
• [28]Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002; 297:253-6.
• [29]Wohnsland F, Faller B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem. 2001; 44:923-30.
• [30]Wan H, Rehngren M, Giordanetto F, Bergström F, Tunek A. High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem. 2007; 50:4606-15.
• [31]Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD et al.. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nature Neurosci. 2004; 7:954-60.